Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy
Open Access
- 6 September 2022
- journal article
- letter
- Published by Springer Nature in Blood Cancer Journal
- Vol. 12 (9) , 1-3
Abstract
No abstract availableKeywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (HHSN261201500071C)
This publication has 14 references indexed in Scilit:
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 studyThe Lancet Oncology, 2020
- Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)Blood, 2019
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple MyelomaNew England Journal of Medicine, 2019
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2019
- Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applicationsAmerican Journal of Hematology, 2019
- A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myelomaJournal of Hematology & Oncology, 2018
- Efficacy and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM)Blood, 2018
- Multiple myeloma epidemiology and survival: A unique malignancySeminars in Oncology, 2016
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaThe Lancet Oncology, 2016
- A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid MalignanciesCancer Investigation, 2015